prikaz prve stranice dokumenta EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE
Access restricted to students and staff of home institution
master's thesis
EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE
Split: University of Split, School of Medicine, 2014. urn:nbn:hr:171:745968
Abaza, Ivan
University of Split
School of Medicine

Cite this document

Abaza, I. (2014). EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE (Master's thesis). Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:745968

Abaza, Ivan. "EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE." Master's thesis, University of Split, School of Medicine, 2014. https://urn.nsk.hr/urn:nbn:hr:171:745968

Abaza, Ivan. "EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE." Master's thesis, University of Split, School of Medicine, 2014. https://urn.nsk.hr/urn:nbn:hr:171:745968

Abaza, I. (2014). 'EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE', Master's thesis, University of Split, School of Medicine, accessed 17 May 2022, https://urn.nsk.hr/urn:nbn:hr:171:745968

Abaza I. EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE [Master's thesis]. Split: University of Split, School of Medicine; 2014 [cited 2022 May 17] Available at: https://urn.nsk.hr/urn:nbn:hr:171:745968

I. Abaza, "EKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE", Master's thesis, University of Split, School of Medicine, Split, 2014. Available at: https://urn.nsk.hr/urn:nbn:hr:171:745968

Please login to the repository to save this object to your list.
Metadata
TitleEKSPRESIJA p53 PROTEINA U TROSTRUKO NEGATIVNIM KARCINOMIMA DOJKE
AuthorIvan Abaza
MentorIvana Mrklić (mentor)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2014, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Gynecology and Obstetrics
Abstract
Cilj istraživanja. Trostruko negativni tumori dojke su grupa tumora karakterizirana negativnim statusom HER2-neu receptora i receptora za steroidne hormone, a čine 10 do 20% karcinoma dojke. Spadaju u skupinu tumora s lošijom prognozom zbog agresivnog ponašanja i nedostatka ciljane terapije. Cilj ovog istraživanja bio je utvrditi razinu ekspresije p53 proteina u trostruko negativnim karcinomima dojke, te njegovu povezanost s kliničkopatološkim prognostičkim pokazateljima, duljinom preživljavanja bez znakova povrata bolesti i ukupnim preživljenjem. Materijali i metode. U studiju su uključene 83 bolesnice operirane u razdoblju od 2003. do 2009., kojima je postavljena dijagnoza karcinoma dojke sa trostruko negativnim imunofenotipom. Uzorci tumora bojani su imunohistokemijski primjenom antitijela za p53, Ki-67, CK5/6, CK14 i EGFR. Bazalni imunofenotip definiran je pozitivnošću na jedan ili više bazalnih markera: CK5/6, CK14 i/ili EGFR. Za usporedbu kategorijskih varijabli korišteni su χ2 test i Mann-Whitneyjev U test, a za usporedbu kvantitativnih varijabli korišten je t-test. U analizi preživljenja korištena je Kaplan- Meierova metoda, Log-rank test, te Coxova uninominalna i multinominalna analiza. Rezultati. Zabilježena je visoka razina ekspresije p53 proteina u trostruko negativnim karcinomima dojke (medijan 40.5%). Najveći broj trostruko negativnih tumora bio je visokog histološkog gradusa (84%). Među tumorima trostruko negativne skupine zabilježene su visoke vrijednosti mitotskog (medijan 25.9/10 VPVP, raspon 2-110) i Ki-67 proliferacijskog indeksa (medijan 53.7%, raspon 3-95). Ekspresija p53 proteina nije statistički značajno korelirala s ispitivanim kliničko-patološkim prognostičkim pokazateljima. Nije dokazan statistički značajan utjecaj ekspresije p53 proteina na duljinu preživljenja bez znakova povrata bolesti, kao ni na ukupno preživljenje (p= 0.872, p=0.595). Zaključak. Visoka razina ekspresije p53 proteina povezuje se s lošijim kliničko patološkim karakteristikama tumora. Iako p53 nije imao prognostički značaj u ovom istraživanju, visoka razina ekspresije p53 proteina zabilježena u trostruko negativnim tumorima značajka je koja potvrđuje da se radi o agresivnijoj skupini tumora.
Abstract (english)
Objectives. Triple negative breast cancer (TNBC) – defined by estrogen receptor, progesteron receptor and human epidermal growth factor 2 negativity, is a group of tumours with poor prognosis, due to aggressive tumour biology, and lack of targeted therapy. The aim of this study was to assess expression of p53 in TNBC, in addition to conventional clinicopathologic factors and to demonstrate its prognostic relevance in this group of tumours. Materials and methods. The study included 83 patients with TNBC who underwent surgery between 2003 and 2009. Formalin fixed paraffin embedded tumour sections were stained immunohistochemicaly for p53, Ki-67, CK5/6, CK14 and EGFR. Basal like (BL) immunophenotype was defined by positivity for one or more basal cell markers: CK5/6, CK14 or EGFR. Correlations between categorical variables were studied using chi-square and Mann-Whitney U test, and t-test was used to compare quantitative variables. For survival analysis Kaplan- Meier method, log-rank test and Cox proportional hazard regression model were used. Results. Triple negative breast carcinomas are group of tumors with high expression of p53 protein (median 40.5 %). The majority of triple negative breast carcinomas had high histological grade (84%), high mitotic score (median 25.9 %), and high proliferation index measured by Ki67 (median 53.7%). High p53 expression in triple negative breast cancers was not significantly correlated with examined clinicopathologic parameters, disease free survivor (p=0.872) and overall survivor (p=0.595). Conclusion. High level of expression of p53 protein is associated with worse clinical pathological characteristics of the tumor. Although p53 had no prognostic significance in this study, high levels of expression of p53 protein observed in the triple negative tumors, confirms that this is a group of aggressive tumors.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:745968
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsAccess restricted to students and staff of home institution
Terms of useLicence In copyright icon
RepositoryMEFST Repository
Created on2016-04-26 11:46:54